NEWTON, Mass.--(BUSINESS WIRE)--Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company committed to bringing therapies that target mitochondrial dysfunction to patients with severe acute and chronic diseases, today announced that Travis Wilson, Chief Executive Officer, is presenting a corporate overview at Piper Jaffray’s 26th Annual Healthcare Conference.
